NCT06557057View on ClinicalTrials.gov

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

RecruitingOBSERVATIONAL

Enrollment

75

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

HER2-Positive Breast Carcinoma

Interventions

OTHER

Non-Interventional Study

Non-Interventional Study

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT06557057 - Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk | Biotech Hunter | Biotech Hunter